An Open-Label, Multicentre, Phase II Study of TVD as Treatment for Children With Stage 4 Neuroblastoma Failing to Respond to First-Line Treatment According to HR-NBL-01/ E-SIOP [Topotecan-Vincristine-Doxorubicin in Children With Stage 4 Neuroblastoma Failing to Respond to COJEC (TVD)].

Trial Profile

An Open-Label, Multicentre, Phase II Study of TVD as Treatment for Children With Stage 4 Neuroblastoma Failing to Respond to First-Line Treatment According to HR-NBL-01/ E-SIOP [Topotecan-Vincristine-Doxorubicin in Children With Stage 4 Neuroblastoma Failing to Respond to COJEC (TVD)].

Completed
Phase of Trial: Phase II/III

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs Doxorubicin (Primary) ; Topotecan (Primary) ; Vincristine (Primary)
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Apr 2011 Planned end date changed from 3 Jan 2010 to 14 Oct 2010 as reported by ClinicalTrials.gov.
    • 20 Jan 2011 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network record.
    • 29 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top